The ratings displayed on this tab are not issued or maintained by EJR in its capacity as an NRSRO.
Diff |
BlueMountain CLO 2016-1 CR | BlueMountain CLO 2016-1 | A (sf) | N/A | | 16.44 | 112.48 | 118 | 1.05 | 115 | 325.61 | 2.83 | 05/07/21 |
BlueMountain CLO 2016-1 DR | BlueMountain CLO 2016-1 | BB+ (sf) | N/A | | 11.62 | 108.42 | 111.56 | 1.03 | 110 | 288.44 | 2.62 | 05/07/21 |
BlueMountain CLO 2016-1 ER | BlueMountain CLO 2016-1 | BB- (sf) | N/A | | 6.58 | 104.7 | 105.54 | 1.01 | 105 | 232.66 | 2.22 | 05/07/21 |
Canyon CLO 2016-1 BR | Canyon CLO 2016-1 | AA+ (sf) | AA | | 23.85 | 123.5 | 131.1 | 1.06 | 120 | 254.44 | 2.12 | 05/07/21 |
Allegro CLO VII B | Allegro CLO VII | AA+ (sf) | AA | | 22.83 | 122.6 | 129.59 | 1.06 | 120 | 340.34 | 2.84 | 05/07/21 |
Canyon CLO 2019-1 B | Canyon CLO 2019-1 | AA- (sf) | AA | | 23.15 | 121.58 | 129.96 | 1.07 | 120 | 280.58 | 2.34 | 05/07/21 |
Zais CLO 11 B | Zais CLO 11 | AA+ (sf) | AA | | 21.84 | 121.58 | 126.85 | 1.04 | 120 | 304.45 | 2.54 | 05/07/21 |
AIG CLO 2019-2 B1 | AIG CLO 2019-2 | AA+ (sf) | AA | | 23.87 | 121.6 | 131.35 | 1.08 | 120 | 270.72 | 2.26 | 05/07/21 |
AIG CLO 2019-2 B2 | AIG CLO 2019-2 | AA+ (sf) | AA | | 23.87 | 121.6 | 131.35 | 1.08 | 120 | 270.72 | 2.26 | 05/07/21 |
Carlyle Global Market Strategies CLO 2016-1 A1R | Carlyle Global Market Strategies CLO 2016-1 | AA+ (sf) | AAA | | 40.25 | 112.48 | 118.6 | 1.05 | 115 | 340.62 | 2.96 | 05/07/21 |
Carlyle Global Market Strategies CLO 2016-1 A2R | Carlyle Global Market Strategies CLO 2016-1 | AA+ (sf) | N/A | | 24.73 | 112.48 | 118.6 | 1.05 | 115 | 340.62 | 2.96 | 05/07/21 |
Carlyle Global Market Strategies CLO 2016-1 BR | Carlyle Global Market Strategies CLO 2016-1 | A+ (sf) | N/A | | 16.85 | 112.48 | 118.6 | 1.05 | 115 | 340.62 | 2.96 | 05/07/21 |
Carlyle Global Market Strategies CLO 2016-1 CR | Carlyle Global Market Strategies CLO 2016-1 | BB+ (sf) | N/A | | 12.04 | 108.42 | 112.11 | 1.03 | 110 | 302.09 | 2.75 | 05/07/21 |
Carlyle Global Market Strategies CLO 2016-1 DR | Carlyle Global Market Strategies CLO 2016-1 | BB (sf) | N/A | | 7.01 | 104.7 | 106.05 | 1.01 | 105 | 248.47 | 2.37 | 05/07/21 |
Broad River BSL Funding CLO 2020-1 A | Broad River BSL Funding CLO 2020-1 | AA+ (sf) | AAA | | 40.78 | 122.6 | 134.09 | 1.09 | 120 | 191.46 | 1.6 | 05/07/21 |
Broad River BSL Funding CLO 2020-1 B | Broad River BSL Funding CLO 2020-1 | AA+ (sf) | AA | | 25.8 | 122.6 | 134.09 | 1.09 | 120 | 191.46 | 1.6 | 05/07/21 |
Broad River BSL Funding CLO 2020-1 C | Broad River BSL Funding CLO 2020-1 | A+ (sf) | A | | 20.78 | 116.2 | 125.6 | 1.08 | 115 | 173.14 | 1.51 | 05/07/21 |
Broad River BSL Funding CLO 2020-1 D | Broad River BSL Funding CLO 2020-1 | BB+ (sf) | BBB- | | 14.79 | 109.5 | 116.76 | 1.07 | 110 | 147.57 | 1.34 | 05/07/21 |
Anchorage Capital CLO 2013-1 BR | Anchorage Capital CLO 2013-1 | A+ (sf) | A | | 21.52 | 120.78 | 127.2 | 1.05 | 110 | 346.09 | 3.15 | 05/07/21 |
AIMCO CLO Series 2018-B A | AIMCO CLO Series 2018-B | AA+ (sf) | N/A | | 35.15 | 123.25 | 132.46 | 1.07 | 120 | 289.68 | 2.41 | 05/07/21 |
AIMCO CLO Series 2018-B B | AIMCO CLO Series 2018-B | AA+ (sf) | N/A | | 24.55 | 123.25 | 132.46 | 1.07 | 120 | 289.68 | 2.41 | 05/07/21 |
AIMCO CLO Series 2018-B C | AIMCO CLO Series 2018-B | A+ (sf) | N/A | | 19.69 | 116.95 | 124.44 | 1.06 | 110 | 262.89 | 2.39 | 05/07/21 |
AIMCO CLO Series 2018-B D | AIMCO CLO Series 2018-B | BB+ (sf) | BBB- | | 13.33 | 109.35 | 115.3 | 1.05 | 105 | 226.52 | 2.16 | 05/07/21 |
AIMCO CLO Series 2018-B E | AIMCO CLO Series 2018-B | BB- (sf) | BB- | | 8.22 | 104.2 | 108.88 | 1.04 | | | | 05/07/21 |
Atlas Senior Loan Fund X CLO B | Atlas Senior Loan Fund X | AA+ (sf) | AA | | 23.32 | 123.53 | 130.3 | 1.05 | 120 | 330.6 | 2.76 | 05/07/21 |
Canyon Capital CLO 2012-1 R B | Canyon Capital CLO 2012-1 R | AA+ (sf) | AA | | 23.4 | 122.94 | 130.2 | 1.06 | 120 | 247.88 | 2.07 | 05/07/21 |
CBAM 2019-10 CLO A1A | CBAM 2019-10 | AA+ (sf) | N/A | | 37.56 | 125.6 | 133.86 | 1.07 | 120 | 248.76 | 2.07 | 05/07/21 |
CBAM 2019-10 CLO A1B | CBAM 2019-10 | AA+ (sf) | N/A | | 37.56 | 125.6 | 133.86 | 1.07 | 120 | 248.76 | 2.07 | 05/07/21 |
CBAM 2019-10 CLO A2 | CBAM 2019-10 | AA+ (sf) | N/A | | 35.67 | 125.6 | 133.86 | 1.07 | 120 | 248.76 | 2.07 | 05/07/21 |
CBAM 2019-10 CLO B | CBAM 2019-10 | AA+ (sf) | N/A | | 25.72 | 125.6 | 133.86 | 1.07 | 120 | 248.76 | 2.07 | 05/07/21 |
CBAM 2019-10 CLO C | CBAM 2019-10 | A+ (sf) | N/A | | 20.56 | 118.8 | 125.17 | 1.05 | 115 | 225.55 | 1.96 | 05/07/21 |
CBAM 2019-10 CLO D | CBAM 2019-10 | BB+ (sf) | N/A | | 14.08 | 111.2 | 115.72 | 1.04 | 110 | 194.67 | 1.77 | 05/07/21 |
CBAM 2019-10 CLO E | CBAM 2019-10 | BB- (sf) | BB- | | 7.66 | 104.6 | 107.67 | 1.03 | | | | 05/07/21 |
Madison Park Funding XLIII (formerly Atrium XIV) CLO A2BR | Madison Park Funding XLIII (formerly Atrium XIV) | AA+ (sf) | N/A | | 36.18 | 122.7 | 130.29 | 1.06 | 120 | 328.23 | 2.74 | 05/07/21 |
Madison Park Funding XLIII (formerly Atrium XIV) CLO B | Madison Park Funding XLIII (formerly Atrium XIV) | AA+ (sf) | AA | | 24.3 | 122.7 | 130.29 | 1.06 | 120 | 328.23 | 2.74 | 05/07/21 |
BlueMountain CLO 2012-2 ARR | BlueMountain CLO 2012-2 | AA+ (sf) | AAA | | 36.19 | 123.24 | 129.61 | 1.05 | 120 | 363.91 | 3.03 | 05/07/21 |
BlueMountain CLO 2012-2 BRR | BlueMountain CLO 2012-2 | AA+ (sf) | N/A | | 24.46 | 123.24 | 129.61 | 1.05 | 120 | 363.91 | 3.03 | 05/07/21 |
BlueMountain CLO 2012-2 CRR | BlueMountain CLO 2012-2 | BBB+ (sf) | N/A | | 16.04 | 112.49 | 116.91 | 1.04 | 115 | 308.14 | 2.68 | 05/07/21 |
BlueMountain CLO 2012-2 DRR | BlueMountain CLO 2012-2 | BB+ (sf) | N/A | | 10.85 | 107.16 | 110.26 | 1.03 | 107.5 | 272.09 | 2.53 | 05/07/21 |
BlueMountain CLO 2012-2 ERR | BlueMountain CLO 2012-2 | B+ (sf) | N/A | | 6.5 | 103.5 | 105.24 | 1.02 | 102.5 | 229.09 | 2.24 | 05/07/21 |
Ares XLII CLO BR | Ares XLII CLO | AA+ (sf) | N/A | | 21.53 | 120.51 | 127.2 | 1.06 | 120 | 312.23 | 2.6 | 05/07/21 |
Zais CLO 6 B | Zais CLO 6 | AA+ (sf) | N/A | | 21.97 | 122.6 | 127.33 | 1.04 | 120 | 300.27 | 2.5 | 05/07/21 |
MP CLO IV (previously ACAS CLO 2013-2) BR | MP CLO IV (previously ACAS CLO 2013-2) | AA+ (sf) | AA | | 22.06 | 123.3 | 128.07 | 1.04 | 120 | 285.59 | 2.38 | 05/07/21 |
ALM XVII CLO A1BR | ALM XVII | AA+ (sf) | N/A | | 36.59 | 117.21 | 124.33 | 1.06 | 115 | 328.06 | 2.85 | 05/07/21 |
ALM XVII CLO BR | ALM XVII | A+ (sf) | N/A | | 20.15 | 117.21 | 124.33 | 1.06 | 115 | 328.06 | 2.85 | 05/07/21 |
Apidos CLO XXV B1R | Apidos CLO XXV | A+ (sf) | A | | 17.24 | 115.8 | 120.79 | 1.04 | 115 | 272.71 | 2.37 | 05/07/21 |
Apidos CLO XXV B2R | Apidos CLO XXV | A+ (sf) | A | | 17.24 | 115.8 | 120.79 | 1.04 | 115 | 272.71 | 2.37 | 05/07/21 |
522 Funding CLO 2017-1(A) (previously Assurant CLO I) B | 522 Funding CLO 2017-1(A) (previously Assurant CLO I) | AA+ (sf) | AA | | 23.28 | 121.6 | 129.15 | 1.06 | 120 | 300.35 | 2.5 | 05/07/21 |
Carlyle U.S. CLO 2017-1 A1B | Carlyle U.S. CLO 2017-1 | AA+ (sf) | AAA | | 33.8 | 114.6 | 119.21 | 1.04 | 115 | 267.8 | 2.33 | 05/07/21 |
Carlyle U.S. CLO 2017-1 B | Carlyle U.S. CLO 2017-1 | BBB+ (sf) | A | | 16.82 | 114.6 | 119.21 | 1.04 | 115 | 267.8 | 2.33 | 05/07/21 |